In Vitro Characterization of Viral Fitness of Therapy-Resistant Hepatitis B Variants

Gastroenterology

Volumn 136, Issue 1, 2009, Pages

  Villet, Stéphanie ^a,b   Billioud, Gaëtan ^a,b   Pichoud, Christian ^a,b   Lucifora, Julie ^a,b   Hantz, Olivier ^a,b   Sureau, Camille ^d   Dény, Paul ^a,e   Zoulim, Fabien ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

^c HÔTEL DIEU   (France)

^d INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^e UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENVELOPE PROTEIN; HEPATITIS ANTIBODY; LAMIVUDINE; HEPATITIS B SURFACE ANTIGEN; VIRUS ENVELOPE PROTEIN;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DELTA AGENT HEPATITIS; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS GENOME; VIRUS PARTICLE; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CELL CULTURE; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MUTATION; PHYSIOLOGY; VIRION; VIRUS ASSEMBLY;

CELLS, CULTURED; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS DELTA VIRUS; HUMANS; MUTATION; VIRAL ENVELOPE PROTEINS; VIRION; VIRUS ASSEMBLY;

EID: 59849117800     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.09.068     Document Type: Article

References (31)

1. Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
2. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131 (2006) 1743-1751
3. Lai C.L., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
4. Villeneuve J.P., Durantel D., Durantel S., et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 39 (2003) 1085-1089
5. Villet S., Pichoud C., Billioud G., et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 48 (2008) 747-755
6. Brunelle M.N., Jacquard A.C., Pichoud C., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2005) 1391-1398
7. Tenney D.J., Levine S.M., Rose R.E., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
8. Villet S., Pichoud C., Villeneuve J.P., et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 131 (2006) 1253-1261
9. Villet S., Ollivet A., Pichoud C., et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 46 (2007) 531-538
10. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25 (2002) 97-106
11. Heermann K.H., and Gerlich W.H. Surface proteins of hepatitis B viruses. In: Mc Lachlan A. (Ed). Molecular biology of the hepatitis B virus (1991), CRC Press, Boca Raton, FL 109-143
12. Torresi J., Earnest-Silveira L., Deliyannis G., et al. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 (2002) 305-313
13. Vietheer P.T., Netter H.J., Sozzi T., et al. Failure of the lamivudine-resistant rtM204I hepatitis B virus mutants to efficiently support hepatitis delta virus secretion. J Virol 79 (2005) 6570-6573
14. Litwin S., Toll E., Jilbert A.R., et al. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 34 Suppl 1 (2005) S96-S107
15. Sureau C., Guerra B., and Lee H. The middle hepatitis B virus envelope protein is not necessary for infectivity of hepatitis delta virus. J Virol 68 (1994) 4063-4066
16. Kuo M.Y., Chao M., and Taylor J. Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol 63 (1989) 1945-1950
17. Gripon P., Rumin S., Urban S., et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 99 (2002) 15655-15660
18. Summers J., Smith P.M., and Horwich A.L. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification. J Virol 64 (1990) 2819-2824
19. Blanchet M., and Sureau C. Analysis of the cytosolic domains of the hepatitis B virus envelope proteins for their function in viral particle assembly and infectivity. J Virol 80 (2006) 11935-11945
20. Le Gal F., Gordien E., Affolabi D., et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 43 (2005) 2363-2369
21. Bonino F., Heermann K.H., Rizzetto M., et al. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol 58 (1986) 945-950
22. Mason W.S., Jilbert A.R., and Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci U S A 102 (2005) 1139-1144
23. Zhou T., Saputelli J., Aldrich C.E., et al. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother 43 (1999) 1947-1954
24. Yamamoto T., Litwin S., Zhou T., et al. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. J Virol 76 (2002) 1213-1223
25. Bartholomew M.M., Jansen R.W., Jeffers L.J., et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349 (1997) 20-22
26. Jaoude G.A., and Sureau C. Role of the antigenic loop of the hepatitis B virus envelope proteins in infectivity of hepatitis delta virus. J Virol 79 (2005) 10460-10466
27. Wallace L.A., Echevarria J.E., Echevarria J.M., et al. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 170 (1994) 1300-1303
28. Oon C.J., Chen W.N., Lim N., et al. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the "a" epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 41 (1999) 113-118
29. Mele A., Tancredi F., Romano L., et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy. J Infect Dis 184 (2001) 905-908
30. Warner N., and Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48 (2008) 88-98
31. Loffler-Mary H., Dumortier J., Klentsch-Zimmer C., et al. Hepatitis B virus assembly is sensitive to changes in the cytosolic S loop of the envelope proteins. Virology 270 (2000) 358-367